Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | GNRHR | P30968 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838081 | 0.93 | MAPT (0.40) | MAPTRORCPOLBSMN1; SMN2MMP3 | |
| SCHEMBL4842787 | 0.92 | MAPT (0.40) | MAPTRORCPOLBSMN1; SMN2MMP3 | |
| SCHEMBL4840174 | 0.90 | RORC (0.41) | MAPTRORCPOLBSMN1; SMN2TRPA1 | |
| SCHEMBL4842584 | 0.90 | MRGPRX4 (0.40) | MAPTRORCGNRHRPOLBALDH1A1 | |
| SCHEMBL4842704 | 0.89 | GNRHR (0.36) | MAPTRORCGNRHRPOLBALDH1A1 | |
| SCHEMBL4841527 | 0.88 | MAPT (0.40) | MAPTRORCALDH1A1SMN1; SMN2MMP3 | |
| SCHEMBL4833497 | 0.88 | TSHR (0.37) | MAPTRORCGNRHRPOLBALDH1A1 | |
| SCHEMBL4838417 | 0.88 | MMP8 (0.44) | MAPTRORCALDH1A1SMN1; SMN2MMP3 | |
| SCHEMBL4842553 | 0.87 | MMP8 (0.41) | MAPTRORCMMP3MMP8 | |
| SCHEMBL4839294 | 0.86 | TRPA1 (0.38) | RORCGNRHRTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | MAPT 763/4885RORC 1777/4885GNRHR 2528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.